Chemi Nutra and Increnovo began a collaboration involving discovery and investigation into PS’s ability to influence cortisol and testosterone levels in exercising and non-exercising men. As a result of these discoveries and subsequent patent filing, the two companies proudly announce the new patent, “Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels” (US Patent No. 8,124,594) was granted on February 28, 2012. Specifically, the patent describes the oral use of PS to maintain healthy testosterone levels, targeted to men experiencing age related declines in testosterone, exercise induced declines in testosterone, and / or hypogonadism.
Scott Hagerman, president of Chemi Nutra said, “There has been a lot of research in recent years involving PS in the sports performance realm - looking at cortisol, stress and immune health, muscle soreness reduction and recovery, and improvements in weightlifting, running, and golf. This exciting new discovery will open additional doors for the use of PS in healthy aging, strength training, and body composition management, in men. I am confident that PS will now move beyond its well-known cognitive enhancing health benefits and into this new area of use, as people become aware of these newest hormone related attributes.”
“For the first time, it is now proven that short-term supplementation with a moderate dose of PS not only prevents a stress induced increase in cortisol concentrations, PS additionally can naturally benefit impaired testosterone levels”, said Dr. Martin Purpura, Managing Member of Increnovo. “These new findings, protected by this recently granted patent, will open new markets for Chemi Nutra’s branded PS, SerinAid PS, for PS-based anti-aging and sports nutrition nutritional supplements.”